

## Erratum

# NICE Cancer Guidance: a description of the Institute's Clinical Guideline Programme

**P Littlejohns, M Eccles and G Leng**

*British Journal of Cancer* (2003) **89**, 2163–2164. doi:10.1038/sj.bjc.6601408 www.bjcancer.com  
© 2003 Cancer Research UK

**Correction to:** *British Journal of Cancer* 2003; **89** (S1), S9–S11 doi: 10.1038/sj.bjc.6601078

Unfortunately, due to an error, the tables were omitted from the above article.

All the three tables (Table 1–3) are reprinted below:

The publisher would like to apologise for any inconvenience this error may have caused.

**Table 1** Range of NICE guidance affecting patients with cancer

### Technology appraisals

Drugs (Paclitaxel, Docetaxel, Trastuzumab, Vinorelbine, Topotecan, Caelyx, Temozolamide, Irinotecan, Oxaliplatin, Raltitxed, Gemcitabine, Vinorelbine, Fludarabine, Imatinib)

Liquid-based cytology

Laparoscopic surgery for colorectal cancer

### Clinical guidelines

Lung cancer

Familial breast cancer

### Cancer service guidances

Breast, urology, haemato-oncological, colorectal, head and neck, child and adolescent, brain and CNS, skin, supportive and palliative care

### Cancer referral guidance

### Confidential enquiries

Review of cancer care in acute units

**Table 2** Key principles underlying the Institute's clinical guidelines

NICE clinical guidelines should:

- aim to improve the quality of clinical care
- address the clinical effectiveness of treatments or management approaches (that is, how well treatments or management approaches work)
- address the cost effectiveness of treatments or management approaches
- be advisory
- be developed through a process that considers all those who might be affected by the guideline (usually including healthcare professionals, patients and their carers, service managers, the wider public, Government and the healthcare industries)
- be based on the best possible research evidence and professional consensus
- be developed using methods that command the respect of patients, the NHS and NHS stakeholders
- be developed with the involvement of patients and healthcare professionals
- set out the clinical care that might reasonably be expected throughout the NHS in England and Wales

**Table 3** The three versions of the clinical guideline

---

**1. NICE GUIDELINE (SHORT VERSION)**

This uses a standard template, and contains:

- the Institute's guidance to the NHS
- implementation advice
- audit advice
- information on the expected impact on NHS resources
- a review date
- a clinical practice algorithm
- details of the Guideline Development Group members

**2. NATIONAL COLLABORATING CENTRE GUIDELINE (FULL VERSION)**

This includes:

- the recommendations
- the profile of treatments and interventions assessed by the Guideline Development Group
- a description of how the evidence was collected, reviewed and assessed
- a description of how the recommendations were formulated and graded
- full reference details of the literature in the evidence base
- details of the Guideline Development Group members
- names of the stakeholders who commented on the first draft of the guideline

**3. INFORMATION FOR THE PUBLIC (PATIENT VERSION)**

This version:

- interprets the recommendations made in the NICE Guideline for patients and carers
  - aims to help patients to make informed choices about their care
  - can be reproduced in patient/carer organisations' own material, with the permission of the Institute
-